Geodon (ziprasidone)

Audience: Neuropsychiatric healthcare professionals

FDA and Pfizer notified healthcare professionals of revision to the WARNINGS section of labeling, describing the increased risk of hyperglycemia and diabetes in patients taking Geodon. FDA has asked all manufacturers of atypical antipsychotic medications, including Pfizer, to add this Warning statement to labeling.

[August, 2004 - Letter - Pfizer]